JPRN-UMIN000008024已完成2 期
Phase II clinical trial of combination chemotherapy with bendamustine and rituximab for relapsed or refractory CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma patients - Bendamustine and rituximab salvage trial for relapsed or refractory CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma patients
Kyoto University Hematology Study Group0 个研究点目标入组 45 人开始时间: 2012年6月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1, pregnant or breast-feeding women 2, patients with active second cancer 3, HBs antigen positive or HBV-DNA positive patients 4, HIV antibody positive patients 5, patients who have been treated with stem cell transplantation 6, interstitial pneumonitis or pulmonary fibrosis 7, patients with central nervous system involvement 8, patients who have already received bendamustine treatment
研究者
相似试验
已完成
不适用
Phase II trial of combination chemotherapy consisting of S-1 and Oxaliplatin in patients with advanced or recurrent mucinous adenocarcinoma of the ovaryMucinous adenocarcinoma of the ovary including metastatic ovarian cancerJPRN-UMIN000001541Japan ovarian mucinous adenocarcinoma study group40
已完成
不适用
Phase II trial of combination chemotherapy consisting of pegylated liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancerEpithelial ovarian cancer, primary fallopian tube cancer, or peritoneal cancer in late relapse (>6 months) after 1st-line chemotherapyJPRN-UMIN000002691Keio University, School of Medicine33
已完成
2 期
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
进行中（未招募）
不适用
Klinisk prövning med kombinationsbehandling av kemoterapi och antikroppar för behandling av patienter med gallgångscancer som inte kan opereras.EUCTR2010-020385-13-SEVejle Hospital78
进行中（未招募）
1 期
Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations - GOC-B-PEUCTR2010-020385-13-DKVejle Hospital